Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

FDA Approves Expanded Label For Grifols' XEMBIFY, The First 20% SCIg For Treatment-Naïve Patients With Primary Humoral Immunodeficiencies; Approval Includes Biweekly Dosing Following Positive Phase 4 Data, Enhancing Flexibility And Convenience For Patients

Author: Benzinga Newsdesk | July 29, 2024 08:01am

Posted In: GRFS